Join Us for the 2024 Colorado Privacy Summit on September 26th!

  • Contact Us

Blog

The Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

Share

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide.

Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform.

See the full episode on

YouTube – https://youtu.be/wbQRAv0q9AQ

Spotify – https://open.spotify.com/show/6JBIzzNVEgtDQg5v3KPGdF

Apple – https://podcasts.apple.com/us/podcast/idea-collider-innovation-asymmetric-learning-in-pharma/id1481841577

Episode Timestamps;

00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma

00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform

02:09 From Cancer Clinic to Pharma: A Patient-First Career Path

06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style

09:37 Vulnerability & Psychological Safety: Building High-Trust Teams

11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis

17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation

18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna

22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions

28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines

33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones

36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point?

Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options.

This episode highlights a pivotal question for the industry:

Are rare diseases at the same inflection point oncology experienced two decades ago?

Don’t forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Michelle Werner;

  1. LinkedIn: https://www.linkedin.com/in/michelle-c-werner/
  2. Website: https://www.alltrna.com/

Follow IDEA Pharma On;

  1. Website: https://www.ideapharma.com/
  2. LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Related Resources

Connect with us on LinkedIn for up-to-the-minute insights

Scroll to Top